IL2 and neoplasm: Immunotherapy using a monoclonal antibody against the tumor-associated disialoganglioside GD2, granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-2 was associated with a significantly improved outcome as compared with standard treatment in patients with neuroblastoma [36].